A LinkedIn post from Glooko highlights the availability of Glooko EndoTool IV Cloud, which brings the company’s EndoTool clinical algorithm into a cloud-based architecture and redesigned user interface. The post positions the product for hospitals expanding their use of enterprise cloud technology.
The post cites a severe hypoglycemia rate of 0.0013% among patients with severely impaired kidney function, presenting the figure as evidence of the system’s performance in a high-risk population. While the metric may support the product’s clinical value proposition, investors would need broader, independently assessed data to evaluate its commercial and medical impact.
According to the post, the updated interface is designed to reduce the number of screens and clicks required for dosing recommendations. Its SaaS model is also described as reducing on-premises infrastructure requirements and supporting deployment across multiple hospitals, which could improve implementation efficiency for larger health systems.
The cloud release may strengthen Glooko’s position in digital diabetes management by combining an established insulin-dosing algorithm with a more scalable delivery model. Potential financial benefits could include recurring software revenue and lower customer deployment friction, although adoption, hospital purchasing cycles, regulatory considerations, and competitive offerings will remain important factors in assessing the opportunity.